IL17A and neoplasm: Since we observed that the level of SDF-1 was significantly reduced with anti-IL-17A antibody treatment, we conducted an in vitro trans-well Boyden chamber assay with the bone or lung lysate in the bottom chamber and the 4 T1 or PyV MT tumor cells in the top chamber.